Zai Lab (Nasdaq:ZLAB) - Aandelenkoers, Nieuws & Analyse

ZLAB Overzicht aandelen

Zai Lab Limited ontwikkelt en commercialiseert therapieën voor de behandeling van oncologie, auto-immuunziekten, infectieziekten en neurowetenschap. Meer informatie

ZLAB fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 85.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 68.17% per jaar groeien

Risicoanalyse

Geen risico's gedetecteerd voor ZLAB uit onze risicocontroles.

Zai Lab Limited Concurrenten

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.7b

Twist Bioscience

NasdaqGS:TWST

US$2.4b

Deciphera Pharmaceuticals

NasdaqGS:DCPH

US$2.2b

Veracyte

NasdaqGM:VCYT

US$3.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Zai Lab
Historische aandelenkoersen
Huidige aandelenkoers	US$25.70
52 Week Hoogtepunt	US$36.60
52 Week Laag	US$13.48
Bèta	1.04
11 maand verandering	-10.83%
3 maanden verandering	42.62%
1 Jaar Verandering	-6.51%
33 jaar verandering	-66.11%
5 jaar verandering	-33.87%
Verandering sinds IPO	42.78%

Recent nieuws en updates

The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 15

Recent updates

The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 15

Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Sep 28

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Sep 23

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Jun 12

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

May 14

A Risky Bet: Zai Lab's Uncertain Future

Apr 16

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24

Rendement voor aandeelhouders

	ZLAB	US Biotechs	US Markt
7D	-3.6%	-6.5%	-1.0%
1Y	-6.5%	14.6%	30.3%

Rendement versus industrie: ZLAB presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 14.6 % opleverde.

Rendement versus markt: ZLAB presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.3 % opleverde.

Prijsvolatiliteit

Is ZLAB's price volatile compared to industry and market?
ZLAB volatility
ZLAB Average Weekly Movement	9.1%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: ZLAB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van ZLAB is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	2,175	Samantha Du	www.zailaboratory.com

Zai Lab Limited ontwikkelt en commercialiseert therapieën voor de behandeling van oncologie, auto-immuunziekten, infectieziekten en neurowetenschap. De commerciële producten omvatten Zejula, een oraal toegediende polymerase 1/2-remmer; Optune, een kankertherapie die gebruikmaakt van elektrische velden afgestemd op specifieke frequenties om tumorcellen te doden; NUZYRA voor acute bacteriële huid- en huidstructuurinfecties en door de gemeenschap opgelopen bacteriële longontsteking; Qinlock voor de behandeling van gastro-intestinale stromale tumoren en VYVGART, een menselijk IgG1-antilichaamfragment voor myesthenia gravis. Het bedrijf ontwikkelt ook Tumor Treating Fields, een draagbaar apparaat voor het toedienen van elektrische velden; Repotrectinib, een tyrosinekinaseremmer (TKI) gericht tegen ROS1 en TRK A/B/C in TKI-naïeve of -behandelde kankerpatiënten; Tisotumab vedotin, een geneesmiddelconjugaat met antilichamen; Adagrasib voor de behandeling van KRAS-G12C-gemuteerde NSCLC, colorectale kanker en pancreaskanker; en Bemarituzumab voor de behandeling van maag- en gastro-oesofageale junctiekankerpatiënten.

Zai Lab Limited Samenvatting

Hoe verhouden de winst en inkomsten van Zai Lab zich tot de beurswaarde?
ZLAB fundamentele statistieken
Marktkapitalisatie	US$2.58b
Inkomsten(TTM)	-US$270.85m
Inkomsten(TTM)	US$355.75m

7.1x

P/S-verhouding

-9.3x

Koers/Winstverhouding

Is ZLAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ZLAB resultatenrekening (TTM)
Inkomsten	US$355.75m
Kosten van inkomsten	US$395.21m
Brutowinst	-US$39.46m
Overige uitgaven	US$231.39m
Inkomsten	-US$270.85m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.75
Brutomarge	-11.09%
Nettowinstmarge	-76.13%
Schuld/Eigen Vermogen Verhouding	16.9%

Hoe presteerde ZLAB op de lange termijn?

Bekijk historische prestaties en vergelijking

ZLAB Overzicht aandelen

Beloningen

Risicoanalyse

Zai Lab Limited Concurrenten

NasdaqGS:ACAD

US$2.7b

NasdaqGS:TWST

US$2.4b

NasdaqGS:DCPH

US$2.2b

NasdaqGM:VCYT

US$3.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million.

Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million.

The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310

Recent updates

Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million.

Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million.

The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310

Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024

Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024

Zai Lab Limited Announces Executive Changes, Effective June 30, 2024

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Insider notifies of intention to sell stock

Consensus estimates of losses per share improve by 16%

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023)

Forecast to breakeven in 2026

A Risky Bet: Zai Lab's Uncertain Future

Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024

Zai Lab Limited, Annual General Meeting, Jun 18, 2024

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Price target decreased by 11% to US$56.44

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Key Executive notifies of intention to sell stock

Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List

Consensus EPS estimates upgraded to US$3.45 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

New minor risk - Profitability

Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Insider exercised options to buy US$295k worth of stock.

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

New minor risk - Share price stability

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth